Dr. Atrash is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 980-442-5241
Summary
- Dr. Shebli Atrash is an oncologist in Charlotte, NC and is affiliated with Atrium Health's Carolinas Medical Center. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 13 years. He also speaks multiple languages, including Arabic. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.
Education & Training
University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 2014 - 2017
St Barnabas HospitalResidency, Internal Medicine, 2008 - 2011
Damascus University Faculty of MedicineClass of 2004
Certifications & Licensure
NC State Medical License 2017 - 2025
SC State Medical License 2023 - 2025
AR State Medical License 2011 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Therapeutic Research in Multiple Myeloma Start of enrollment: 2003 Aug 01
- UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Start of enrollment: 2008 Jul 01
- Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Start of enrollment: 2009 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 125 citationsExtramedullary multiple myelomaManisha Bhutani, David M. Foureau, Shebli Atrash, Peter M. Voorhees, Saad Z. Usmani
Leukemia. 2020-01-01 - 1 citationsA Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.Manisha Bhutani, David M Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova
Clinical Lymphoma, Myeloma & Leukemia. 2023-07-01 - 13 citationsTreatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study.Shebli Atrash, Philippe Thompson-Leduc, Ming-Hui Tai, Shuchita Kaila, Kathleen Gray
BMC Cancer. 2021-11-12
Press Mentions
Dr. Atrash on Investigational Combinations with Venetoclax in Relapsed/Refractory Multiple MyelomaFebruary 10th, 2020- Dr. Atrash on the BELLINI Trial Results in Relapsed/Refractory Multiple MyelomaFebruary 3rd, 2020
Committees
- Member, SWOG 2019 - Present
- member, ACCRU 2019 - Present
- Member, International Myeloma Working Group 2019 - Present
Professional Memberships
- Member
- Member
- Member
- European Hematology AssociationMember
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
